Last reviewed · How we verify
Carmustin
Carmustin, marketed by University Hospital Freiburg, is indicated for diffuse non-Hodgkin's lymphoma, large cell, with a key composition patent expiring in 2028. The drug's market position is bolstered by its established mechanism and indication, though specific revenue figures are not available. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Carmustin |
|---|---|
| Also known as | BCNU, Bis-Chlorethyl-Nitrosourea |
| Sponsor | University Hospital Freiburg |
| Target | Glutathione reductase, mitochondrial |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Diffuse non-Hodgkin's lymphoma, large cell
- Glioblastoma multiforme of brain
- Glioma, malignant
- Hodgkin's disease
- Malignant neoplasm of brain
- Multiple myeloma
- Non-Hodgkin's lymphoma
Common side effects
- Nausea
- Vomiting
- Renal toxicity
- Pneumonitis
- Pulmonary toxicity
- Myelosuppression
- Anorexia
- Diarrhea
- Alopecia
- Hyperpigmentation
- Erythema
- Headaches
Serious adverse events
- Interstitial lung disease
- Renal failure
- Veno-occlusive disease
- Acute leukemia
- Bone marrow dysplasias
- Encephalopathy
- Seizures
- Skin necrosis
- Opportunistic infection
- Conjunctival hemorrhage
Key clinical trials
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma (PHASE2)
- Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (PHASE4)
- Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PHASE2)
- A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant (PHASE1)
- Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
- Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (PHASE2)
- Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carmustin CI brief — competitive landscape report
- Carmustin updates RSS · CI watch RSS
- University Hospital Freiburg portfolio CI